ORYZON Reports First Dosing in Phase 1 Study of Alzheimer’s Drug Treatment

ORYZON Reports First Dosing in Phase 1 Study of Alzheimer’s Drug Treatment
Oryzon Genomics recently announced the dosing of a first subject in its Phase 1 trial of oral LSD1-MAOB dual selective inhibitor ORY-2001, targeting memory loss and cognitive decline in Alzheimer's disease. The single and multiple ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of ORY-2001 in healthy subjects. The trial is randomized, double-blind, and placebo-controlled, and is being conducted in a clinical unit of a university hospital in Barcelona, Spain, pursuant to a Clinical Trial Application (CTA) from the Spanish Drug Agency (AEMPS). If the study's outcome is positive, Oryz
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *